Vaxart nears key COVID-19 vaccine pill trial readout after turbulent year
By
Rowan Walrath
Summary
Vaxart, a San Diego-based vaccine developer, is aiming to recover and refocus after a turbulent year. The company is weeks away from a key data readout from its COVID-19 vaccine-pill trial, which could be a pivotal moment for its oral vaccine platform.
Source
bskyVaxart nears key COVID-19 vaccine pill trial readout after turbulent yearcen.acs.orgKey quotes
· 1 pulled‘We’re prepared for whatever the FDA wants’: A vaccine developer gets back on track
You might also wanna read
Undisclosed Deaths in the Pfizer mRNA Covid-19 Vaccine Trial [pdf]
HHS Ends mRNA Vaccine Development Under BARDA Following Review
The U.S. Department of Health and Human Services (HHS) has announced the wind-down of its mRNA vaccine development activities under BARDA, i
hhs.gov·10mo ago
Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and mas
statnews.com·7mo ago
FDA advisory panel unanimously votes to approve Moderna's mRNA flu vaccine after Trump appointee tried to block review
FDA independent advisors voted 9-0 to recommend approval of Moderna's mRNA seasonal flu vaccine (mRNA-1010), despite a Trump appointee at th
arstechnica.com·3d ago
ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted
An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient
ja.ma·5d ago
BEACONs: A novel nanoparticle adjuvant approach for mucosal vaccination against genital herpes
This article presents research on a novel adjuvant called BEACONs (Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles) deve
scim.ag·1d agoComments
Sign in to join the conversation.
No comments yet. Be the first.